Skip to main content
  • Saved

made a Post

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Source :

https://jitc.bmj.com/content/8/2/e000734.full

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells.